These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35196947)

  • 1. Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps.
    Rizzo A; Palmiotti G
    Expert Opin Investig Drugs; 2022 Apr; 31(4):331. PubMed ID: 35196947
    [No Abstract]   [Full Text] [Related]  

  • 2. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.
    Casadei-Gardini A; Tada T; Shimose S; Kumada T; Niizeki T; Cascinu S; Cucchetti A
    Target Oncol; 2021 Mar; 16(2):249-254. PubMed ID: 33638735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Hou Y; Wu B
    Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
    [No Abstract]   [Full Text] [Related]  

  • 6. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
    Rizzo A; Ricci AD; Brandi G
    Immunotherapy; 2021 Jun; 13(8):637-644. PubMed ID: 33820447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
    Minot-This MS; Edeline J
    Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
    [No Abstract]   [Full Text] [Related]  

  • 9. Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
    Fencer MG; Davis CH; Liu J; Galan MA; Spencer KR
    J Investig Med High Impact Case Rep; 2022; 10():23247096221129470. PubMed ID: 36541195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
    Chen Z; Lu X; Koral K
    Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Iwamoto H; Shimose S; Niizeki T; Koga H; Torimura T
    Clin Mol Hepatol; 2022 Jul; 28(3):575-579. PubMed ID: 35443321
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter?
    Kao WY; Su CW
    Liver Int; 2022 Dec; 42(12):2597-2598. PubMed ID: 36415175
    [No Abstract]   [Full Text] [Related]  

  • 13. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world.
    Zhang J; Fang J; Xun Z; Xu Y; Lu X; Zhao H
    Hepatology; 2022 Oct; 76(4):E84-E85. PubMed ID: 35604038
    [No Abstract]   [Full Text] [Related]  

  • 17. An update on atezolizumab for hepatocellular carcinoma.
    Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
    Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Case of Successful Treatment of Recurrent Peritoneal Dissemination of Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Combination Therapy].
    Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Shinke G; Katsuyama S; Ikeshima R; Kawai K; Hiraki M; Sugimura K; Masuzawa T; Takeno A; Hata T; Murata K
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):2027-2029. PubMed ID: 35045482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab and bevacizumab for HCC in the real world.
    Choo SP; Nahon P
    Liver Int; 2022 Apr; 42(4):727-728. PubMed ID: 35289074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.